FDA approves Pfizer’s Vyndaqel, Vyndamax for cardiomyopathy in rare protein disorder
An analyst wrote that the drug's high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam's Onpattro.
transthyretin-mediated amyloidosis